Sanjeev M Bijukchhe, Meeru Gurung, Bhishma Pokhrel, Mila Shakya, Dikshya Pant, Pratistha Maskey, Himang Maskey, Babita Dhakal, Shristy Rajkarkinar, Sabitri Bista, Merryn Voysey, Yama F Mujadidi, Young Chan Kim, Rachel Atherton, Elizabeth Jones, Florence Mclean, Sonu Shrestha, Matilda Hill, Katherine Theiss Nyland, Sarah Kelly, Peter O'reilly, Ganesh Prasad Sah, Buddha Basnyat, Andrew J Pollard, Shrijana Shrestha
BACKGROUND: Previously, the Vi-typhoid conjugate vaccine (Vi-TT) was found to be highly efficacious in Nepalese children under 16 years of age. We assessed the immunogenicity of Vi-TT at 9 and 12 months of age and response to a booster dose at 15 months of age. METHODS: Infants were recruited at Patan Hospital, Kathmandu and received an initial dose of Vi-TT at 9 or 12 months of age with a booster dose at 15 months of age. Blood was taken at four timepoints, and antibody titres were measured using a commercial ELISA kit...
February 22, 2024: Vaccine